Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

Bibliography

• Ferguson T, Wilcken N, Vagg R, Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;CD004421
   Google Scholar
• Piccart-Gebhart MJ, Burzykowski T, Buyse M, Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-6
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK, Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-17
   PubMed Web of Science ®Google Scholar
• Available from: http://www.abraxane.com/resources/Abraxane_Healthcare_ Professional_Prescribing_Information.pdf
   Google Scholar
• Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268:1051-6
   PubMed Web of Science ®Google Scholar
• Irizarry LD, Luu TH, McKoy JM, Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action. Community Oncol 2009;132-4
   Google Scholar
• Gelderblom H, Verweij J, Nooter K, The drawbacks and advantages of vehicle selectionfor drug formulation. Eur J Cancer 2001;37:1590-8
   PubMed Web of Science ®Google Scholar
• Authier N, Gillet JP, Fialip J, Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001;3:301-6
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006;17:735-49
   PubMed Web of Science ®Google Scholar
• Desai NP, Trieu V, Hwang LY, Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• Chin D, Boyle GM, Williams RM, Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005;113:789-97
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Brekken RA, Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80
   PubMed Web of Science ®Google Scholar
• Watkins G, Douglas-Jones A, Bryce R, Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-72
   PubMed Web of Science ®Google Scholar
• Von Hoff D, Ramanathan E, Borad M, SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study [abstract 4525]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Markovic SN, Suman VJ, Kottschade LA, A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: final data from N057E [abstract 9055]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Mirtsching B, Cosgriff T, Harker G, Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012). J Clin Oncol 2008;26(Suppl): abstract 1118
   Google Scholar
• Volk LD, Flister MJ, Bivens CM, Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-8
   PubMed Web of Science ®Google Scholar
• Nyman DW, Campbell KJ, Hersh E, Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-93
   PubMed Web of Science ®Google Scholar
• Cuppone F, Bria E, Carlini P, Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 2008;113:238-46
   PubMedGoogle Scholar
• Berstein JA, Mehta R. In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -> weekly carboplatin and albumin-bound paclitaxel (nab-TC)/trastuzumab (H)/bevacizumab (B) in large and inflammatory breast cancer (BC): a phase II study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):11078
   Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a Phase III trial. J Clin Oncol 2005;23:1-10
   PubMed Web of Science ®Google Scholar
• Davidson N, Tjulandin S, O'shaughnessy J, Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline. Eur J Cancer 2008;218(Suppl 6): abstract 569
   Google Scholar
• Vukelja SJ, O'shaughnessy J, Krasnojon D, Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl): abstract 108242
   Google Scholar
• Guan Z, Feng F, Li QL, Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):1038
   Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26
   PubMed Web of Science ®Google Scholar
• Blum JL, Savin MA, Edelman G, Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6
   PubMed Web of Science ®Google Scholar
• Roy V, LaPlant BR, Gross GG, ; North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53
   PubMed Web of Science ®Google Scholar
• Somer BG, Schwartzberg LS, Arena F, Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):1053
   Google Scholar
• Danso MA, Blum JL, Robert NJ, Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol 2008;26(Suppl): abstract 1075
   Google Scholar
• Gluck S, Lobo C, Reis I, Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl): abstract 1089
   Google Scholar
• Conlin AK, Hudis CA, Bach A, Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl 15s); abstract 1006
   Google Scholar
• Seidman AD, Conlin AK, Bach A, Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl): abstract 1047
   Google Scholar
• Rastogi P, Anderson SJ, Bear HD, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85 Erratum in: J Clin Oncol 2008;26:2793
   PubMed Web of Science ®Google Scholar
• Inhorn RC, Daniel B, Daniel D, Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel. J Clin Oncol 2009;27(Suppl 15s): abstract 618
   Google Scholar
• Paz IB, Lau S, Garberoglio C, Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients with stage II – III breast cancer (BC). J Clin Oncol 2008;26(Suppl): abstract 567
   Google Scholar
• Yardley DA, Raefsky E, Castillo R, Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol 2009;27(Suppl 15s): abstract 527
   Google Scholar
• Robidoux A, Buzdar AU, Quinaux E, A phase II neoadjuvant trial of sequential weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81-6
   PubMed Web of Science ®Google Scholar
• Veerapaneni A, Boisvert M, Choi A, Aggarwal A. Capecitabine and ABI-007 chemotherapy as neoadjuvant treatment of locally advanced breast cancer. J Clin Oncol 2008;26(Suppl): abstract 11535
   Google Scholar
• Dickler MN, Traina T, Panageas K, Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): cardiac safety. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):567
   Google Scholar
• McArthur HL, Rugo H, Nulsen B, Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer [abstract 4104]. San Antonio, TX. Breast Cancer Symposium 10 – 15 December; 2008
   Google Scholar
• Pippen J, O'shaughnessy J, Krekow L, Adriamycin plus cytoxan followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study [abstract 0151]. 11th International Conference on Primary Therapy of Early Breast Cancer; 11 – 14 March 2009; St Gallen, Switzerland
   Google Scholar
• Citron ML, Berry DA, Cirrincione C, Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9
   PubMed Web of Science ®Google Scholar
• Pippen J, Paul D, Richards D, Dose-dense nab-paclitaxel vs paclitaxel with bevacizumab following adriamycin and cytoxan is safe as adjuvant therapy in patients with early-stage breast cancer [abstract 0152]. 11th International Conference on Primary Therapy of Early Breast Cancer; 11 – 14 March 2009; St Gallen, Switzerland
   Google Scholar
• Jones S, Holmes FA, O'shaughnessy J, Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009;27:1177-83
   PubMed Web of Science ®Google Scholar
• Raefsky E, Inhorn R, Lange M, Preliminary safety results from a multicentre phase II trial of nanoparticle-albumin bound paclitaxel/cyclophsphamide in early breast cancer plus trastuzumab in HER-+ patients (pts). J Clin Oncol 2009;27(Suppl 15s): abstract e11509
   Google Scholar
• Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010;119(3):717-24
   Google Scholar
• Hnasko R, Lisanti MP. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003;3:445-64
   PubMedGoogle Scholar
• Pinilla SM, Honrado E, Hardisson D, Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90
   PubMed Web of Science ®Google Scholar
• Savage K, Lambros MB, Robertson D, Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13:90-101
   PubMed Web of Science ®Google Scholar
• Savage K, Leung S, Todd SK, Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008;110:245-56
   PubMed Web of Science ®Google Scholar
• Elsheikh SE, Green AR, Rakha EA, Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008;99:327-34
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Dasgupta A, Sotgia F, An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009;174:2023-34 Epub 2009 May 1
   PubMed Web of Science ®Google Scholar
• Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003;3:571-81
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a Phase III trial. J Clin Oncol 2005;23(31):1-10
   Google Scholar
• Available from: http://nano.cancer.gov
   Google Scholar